volume 51 issue 29 pages 6301-6304

Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.

Publication typeJournal Article
Publication date2015-01-27
scimago Q1
wos Q2
SJR1.037
CiteScore7.4
Impact factor4.2
ISSN13597345, 1364548X
PubMed ID:  25644651
Materials Chemistry
Metals and Alloys
Surfaces, Coatings and Films
General Chemistry
Ceramics and Composites
Electronic, Optical and Magnetic Materials
Catalysis
Abstract
Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells. Mechanistic investigation was carried out on this dual-targeting Pt(IV) prodrug, chalcoplatin. The prodrug effectively entered cancer cells and arrested the cell cycle at the S and G2/M phases, distinctive of that from cisplatin. Chalcoplatin significantly induced p53 activation as well as the subsequent apoptosis pathways. This unique mode of action renders chalcoplatin remarkably cytotoxic and makes this compound among the first examples of a Pt(IV) prodrug that directly interacts with the downstream pathway after the formation of Pt-DNA lesions.
Found 
Found 

Top-30

Journals

1
2
3
4
5
6
7
8
Dalton Transactions
8 publications, 8.33%
European Journal of Medicinal Chemistry
6 publications, 6.25%
Inorganic Chemistry
6 publications, 6.25%
Angewandte Chemie
5 publications, 5.21%
Journal of Inorganic Biochemistry
5 publications, 5.21%
Coordination Chemistry Reviews
5 publications, 5.21%
Angewandte Chemie - International Edition
5 publications, 5.21%
International Journal of Molecular Sciences
4 publications, 4.17%
Bioinorganic Chemistry and Applications
3 publications, 3.13%
Inorganica Chimica Acta
3 publications, 3.13%
Journal of Medicinal Chemistry
3 publications, 3.13%
Inorganic Chemistry Frontiers
3 publications, 3.13%
Bioorganic and Medicinal Chemistry
2 publications, 2.08%
European Journal of Inorganic Chemistry
2 publications, 2.08%
Applied Organometallic Chemistry
2 publications, 2.08%
Chemistry - An Asian Journal
2 publications, 2.08%
Bioconjugate Chemistry
2 publications, 2.08%
Chemical Reviews
2 publications, 2.08%
Chemical Science
2 publications, 2.08%
Chemical Communications
2 publications, 2.08%
Advances in Inorganic Chemistry
2 publications, 2.08%
Analytical Chemistry
1 publication, 1.04%
Frontiers in Chemistry
1 publication, 1.04%
Science China Chemistry
1 publication, 1.04%
Journal of Controlled Release
1 publication, 1.04%
Nanotechnology
1 publication, 1.04%
Biochemical Pharmacology
1 publication, 1.04%
Bioorganic Chemistry
1 publication, 1.04%
Analytica Chimica Acta
1 publication, 1.04%
1
2
3
4
5
6
7
8

Publishers

5
10
15
20
25
30
Elsevier
30 publications, 31.25%
Wiley
19 publications, 19.79%
Royal Society of Chemistry (RSC)
17 publications, 17.71%
American Chemical Society (ACS)
16 publications, 16.67%
MDPI
5 publications, 5.21%
Hindawi Limited
3 publications, 3.13%
Frontiers Media S.A.
1 publication, 1.04%
Springer Nature
1 publication, 1.04%
IOP Publishing
1 publication, 1.04%
Walter de Gruyter
1 publication, 1.04%
Bentham Science Publishers Ltd.
1 publication, 1.04%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 1.04%
5
10
15
20
25
30
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
96
Share
Cite this
GOST |
Cite this
GOST Copy
Ma L. et al. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action. // Chemical Communications. 2015. Vol. 51. No. 29. pp. 6301-6304.
GOST all authors (up to 50) Copy
Ma L., Ma R., Wang Y., Zhu X., Zhang J., Chan H. C., Chen X. F., Zhang W., Chiu S. K., Zhu G. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action. // Chemical Communications. 2015. Vol. 51. No. 29. pp. 6301-6304.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1039/C4CC10409A
UR - https://doi.org/10.1039/C4CC10409A
TI - Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.
T2 - Chemical Communications
AU - Ma, Lili
AU - Ma, Rong
AU - Wang, Yiping
AU - Zhu, Xiaoyue
AU - Zhang, Junliang
AU - Chan, Hoi Ching
AU - Chen, X F
AU - Zhang, Wen-Jun
AU - Chiu, Sung Kay
AU - Zhu, Guangyu
PY - 2015
DA - 2015/01/27
PB - Royal Society of Chemistry (RSC)
SP - 6301-6304
IS - 29
VL - 51
PMID - 25644651
SN - 1359-7345
SN - 1364-548X
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2015_Ma,
author = {Lili Ma and Rong Ma and Yiping Wang and Xiaoyue Zhu and Junliang Zhang and Hoi Ching Chan and X F Chen and Wen-Jun Zhang and Sung Kay Chiu and Guangyu Zhu},
title = {Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.},
journal = {Chemical Communications},
year = {2015},
volume = {51},
publisher = {Royal Society of Chemistry (RSC)},
month = {jan},
url = {https://doi.org/10.1039/C4CC10409A},
number = {29},
pages = {6301--6304},
doi = {10.1039/C4CC10409A}
}
MLA
Cite this
MLA Copy
Ma, Lili, et al. “Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action..” Chemical Communications, vol. 51, no. 29, Jan. 2015, pp. 6301-6304. https://doi.org/10.1039/C4CC10409A.
Profiles